Introduction
Pathological angiogenesis and development of macular edema in the case of diabetic retinopathy depends first of all on the level of blood vessel endothelial growth factor (VEGF-А), the existence of which was proposed back in 1948 by I.C. Michaelson, calling it "Factor-Х" [1] . A number of studies showed occurrence of the increased concentration of the growth factor in the fluid of front chamber and in the vitreous body of the patients having diabetic retinopathy (DR) [2] [3] [4] and diabetic macular edema [4] [5] [6] . Direct correlative dependence was discovered between the level of VEGF in the fluid of front chamber or vitreous body and severity of the proliferative process, as well as lack of dependence of the process severity on the factor concentration in blood plasma [3, 7, 8] . However, in accordance with M.R. Manaviat, serum levels of VEGF can be used for the dynamics of diabetic retinopathy [9] . The highest figures of VEGF were discovered in the case of patients with a secondary neovascular glaucoma [10, 11] .
In accordance with K. Shinoda, availability of VEGF in the fluid of the front chamber in the case of patients with proliferative diabetic retinopathy does not depend on the disease duration such as diabetes mellitus, occurrence of arterial hypertension and nephropathy [12] .
Studies of intraocular fluid from the point of view of availability of the growth factor appeared very informative, however, they cannot be carried out on a regular basis for the evaluation of angiogenesis activity in connection with their obvious invasive nature.
In line with a large amount of literature devoted to determination of VEGF in the fluid of the front chamber, vitreous body, blood serum and plasma, there are not so many researches concerning the factor concentration in a lacrimal fluid. At present single studies of the evaluation of VEGF in a lacrimal fluid are carried out.
These studies discovered direct correlative dependence between the stage of the process and the factor concentration in a lacrimal fluid, as well as its real level of reduction after transscleral diode panretinal coagulation, especially in combination with angiogenesis inhibitors [13, 14] . Maximum level of the factor in a lacrimal fluid is determined in the case of secondary neovascular glaucoma when proliferation is spread to the front eye region [13, 15] .
The carried out studies are single ones, they are carried out with a restricted clinical material with the use of different test systems and various methods of tear collection. A very urgent, in our opinion, issue is continuing to study the level of vasoproliferative factor in the lacrimal fluid in order to evaluate the efficiency of various treatment methods, including panretinal coagulation, the state of angiogenesis in non-transparent optical media, using non-invasive method.
The goal of this study is determination of VEGF-А level in a lacrimal fluid of the patients having different stages of diabetic retinopathy, as well as within different terms after execution of panretinal laser coagulation.
Materials and Methods
The study consisted of two stages. At the first stage the level of VEGF-А in a lacrimal fluid of 56 persons (96 eyes) having diabetes mellitus of the II type was discovered, of them 11 persons (11 eyes) had no traits of diabetic retinopathy and 45 patients (85 eyes) suffered from diabetic retinopathy of different severity level but without traits of neovascularization of the front eye region in accordance with ETDRS,2005 classification (Table 1) .
At the second stage the dynamics of the level of VEGF-А in a lacrimal fluid of 9 patients (18 eyes) was evaluated with pre-and proliferative diabetic retinopathy in 3, 6 and 12 months after carrying out panretinal laser coagulation.
Comprehensive ophthalmological study included ophthalmoscopy with the use of Goldman lens and carrying-out of fluorescence angiography with the help of fundus-camera "Тopcon TDС 50 DX" (Topcon, Japan) for exact determination of retinopathy stage.
Collection of the lacrimal fluid was carried out in a medical treatment room with a partially thrown back head. The patients inhaled vapours of liquid ammonia.
A tear appearing in response to this irritation was collected from a lower conjunctival arch with the help of a micropipette with a sterile tip. The collected fluid with the volume of 50 microliters was placed into microvials "Eppendorf" and was prone to freezing at once at the temperature of -20°С. After defrosting the content of VEGF-A was determined by method of immune-enzyme analysis with the use of test systems "Human VEGF-A Platinum BMS277/2* RUO ELISA Kit" (BioSource International Inc., USA), having high sensitivity degree (2 pg/ml) and recommended for use in compliance with scientific research purposes.
Panretinal coagulation was carried out with the help of "yellow" laser (Quantel Medical SA, France) with the wavelength of 577 nm. The spot diameter comprised 300 micrometers, the impulse duration was 0.05. Full scope of treatment was implemented within 3 treatment sessions during 2 months.
The mathematical and statistical study data processing was carried out with the help of Excel table editor, in particular, its modules such as "Data Analysis" surgical operation, in 1, 3, 6, 12 months) dispersion analysis was used. The dispersion analysis allowed to calculate average score values at each profile of the study, to calculate and build 95% confidence intervals, as well as evaluate the meaning of average value differences.
Results and Their Discussion
All the patients showed availability of VEGF-А in tears. The patients without traits of diabetic retinopathy had average values of vasoproliferative factor comprising 1 425.5±257.3 pg/ml. In the case of non-proliferative diabetic retinopathy of the 1-3 stages (NPDR 1-3) the level of VEGF-A was statistically significantly (p=0.001) higher than in the case of the patients without traits of DR which is reasonable and coincides with the available literature data concerning its level in intraocular fluids. In case of proliferative DR of the 1-3 stage (PDR 1-3) the parameters remained at the same level (p=0.96) which does not coincide with our ideas of angiogenesis and the data concerning the content of VEGF in a vitreous body and the fluid of the front chamber and, of course, it requires additional study. At the severe stage of proliferative retinopathy (PDR 4) the level of vasoproliferative factor statistically significantly (p=0.0003) reduced. At the terminal stage of proliferative retinopathy (PDR 5), but having no traits of neovascular glaucoma, the level of VEGF-A was lower than that in the eyes without retinopathy. Such reduction of VEGF, in our opinion, can be explained by a large-scale destruction of retina which at these stages of the disease stops to produce a vasoproliferative factor (Table 1, Figure 1 ).
Completing the second stage of the study and observing the patients in 3 months after PRC with the volume of 2 541±156.34 coagulates, the level of VEGF-A increased (р=0.074), at that in the case of 33.3% of eyes the process activity which was evaluated in accordance with the dynamics of the region, appearance of new areas of neovascularization and the area of ischemic regions, increased in accordance with angiography data, in 33.3% of cases it stabilized and in 33.3% of cases it decreased.
In 6 months of observation the level of VEGF-A began reducing, practically going back to initial values (р=0.649). The activity of neovascular process reduced slightly, but also statistically insignificantly (р=0.575403).
In 12 months of observation further reduction of the level of VEGF-A took place, which appeared statistically lower in comparison with the scores discovered by the 3 rd month of observation (р=0.012) and was insignificant in comparison with the initial values. At that angiographic activity of neovascularization reduced in 55.56% of cases which appeared statistically significant in comparison with the process activity after 3 and 12 months of observation (р=0.042980) ( Table 2, fig. 2).
Conclusion
Significant and statistically significant increase of VEGF-А in a lacrimal fluid of the patients having diabetic retinopathy was discovered in comparison with the data obtained from the patients having diabetes mellitus, but having no traits of diabetic retinopathy. No statistically significant difference was discovered in the level of VEGF-A of the patients with non-proliferative and proliferative retinopathy of the 1-3 stages. At the same time the patients with a severe retinopathy when fatal changes of the retina and vitreous body were discovered (detachment, expressed gliosis) but no traits of neovascularization of the front eye region were available, showed significant reduction of the level of vasoproliferative factor (Table 1, fig. 1 ).
Panretinal coagulation led to the increase of the level of VEGF-A by 3 months of observation accompanied by increase in the activity of neovascular process in 33.3% of cases. By 6 month of observation the average level of VEGF-A reduced practically to initial values and continued reduction by 12 months, which correlated to the reduction of angiographic activity of neovascularization.
Further studies on a more volumetric clinical material are necessary for the purpose of determining the possibility of using VEGF-А testing in a tear for the evaluation of other methods efficiency for the treatment of diabetic retinopathy and macular edema. Before the treatment 6 months after PRC 3 months after PRC 12 months after PRC
